Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
about
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsReview of the current targeted therapies for non-small-cell lung cancerTargeted therapies in development for non-small cell lung cancerCIViC databaseTwo novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibProgression and metastasis of lung cancerDevelopment and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.Molecular pathways and therapeutic targets in lung cancerHeterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report.Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancerALK inhibitors in non-small cell lung cancer: crizotinib and beyond.Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsGenomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.Molecular chess? Hallmarks of anti-cancer drug resistanceBiomarkers and targeted systemic therapies in advanced non-small cell lung cancerTargeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancerALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer.Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Acquired resistance to TKIs in solid tumours: learning from lung cancer.A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer.Crizotinib in the management of advanced-stage non-small-cell lung cancer.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Novel ALK inhibitors in clinical use and development.Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
P2860
Q26795555-95EED6CF-2AD2-4F7C-8C1E-F80CF1E4B950Q26820845-A2FE4928-F0E9-49B7-8BA2-FC2CEF4A848EQ27015079-28A17600-FAB3-4908-802C-5F565CC09EC9Q27022852-F394D062-A101-4F2E-B0FA-577F84049A16Q27612411-BD559BD1-D290-4BED-823E-45AA09EBA7F4Q27853072-46BE786C-AEE4-4875-B004-21B284DBC920Q28066865-8F783D58-335F-4687-BC99-07B51F54F8F4Q33570096-C83CAEC7-3B86-48A0-A0DB-4D469FF19D16Q33688872-848CFBA9-31D7-4BCD-8D52-F715F1AD4A30Q34293223-E523E0BB-55EC-4F15-9F19-739213A2F97EQ34392733-34A1FE82-C740-4F37-965B-3C3452CAF1CEQ34431889-29BEB7A5-89D5-4F67-874D-32D98146A096Q34781380-F5E4C5E3-490A-4831-A096-DEB1B048508EQ35256603-133F5629-8C07-4C7E-9737-3FC01DDF1A4EQ35858617-29FBBB12-341B-45A6-A6AC-81E78CA98133Q35979767-80A33F51-E5E1-49B3-9D04-07C868A05D4CQ36114660-3B7E1C30-5DD7-4E7E-AC1B-D22321069B23Q36201454-4A0E300D-C2AF-449B-8CE2-B4ED03A9BF08Q36240941-9871B78A-504C-4AC5-A0C5-44223567380CQ36260477-9730C467-0795-47BD-9EA0-02CD29957AA3Q36545592-86ED78EF-1047-4FE9-A7FC-2BDDF0A7B5ADQ36821217-CD6D39A9-9636-4CE4-9877-4024D6F3669AQ36924440-3238F70A-085D-4D5F-A999-8BB3CA636F39Q37246286-505689DC-453D-4851-8BBF-A1F89D2DD93DQ37416902-38FFC2E2-5D38-46AA-BB55-C95105425BDDQ37566828-96FAA282-C7D1-4C14-877E-0FD08CB73C11Q37626056-8189128B-E5EB-429D-ACCA-0A3758BF3122Q37634419-F8562DCD-EFDC-45C7-A5FF-0510B66B3031Q37706697-DDC4F958-6A84-4141-BA03-E3AB671E0F15Q38148969-2C2FB136-B9D7-4D99-8451-D810A3E89650Q38224967-5DEB97DD-213E-4606-9D53-DAC5FD71B432Q38237654-B0ADB591-4FD9-441E-A43B-DD289BE9E7D7Q38245669-7D0AD842-B3B0-477D-B5A1-6416D2C81CEAQ38372437-A3FBDFAC-2156-4EB8-A796-2B52FF7CD9F0Q38390200-758EF160-EFDB-425F-91A6-28B121206753Q38427240-86CCD22C-F5CF-4715-A163-7524EA89FD75Q38461723-13671ED1-5672-4731-ABAD-868B2A50A22EQ38631019-937B65BA-DD9F-4E11-B1A7-D0E5DCF4A84BQ38638022-579168B2-FDEF-4E38-AD24-546F94F7EBB2Q38663460-52584505-1E98-4FA0-8F25-87D36D0E7345
P2860
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@ast
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@en
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@nl
type
label
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@ast
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@en
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@nl
prefLabel
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@ast
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@en
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer.
@nl
P2093
P3181
P1476
Heterogeneity of genetic chang ...... in ALK-rearranged lung cancer
@en
P2093
Bhumsuk Keam
Dae Seog Heo
Dong-Wan Kim
Doo Hyun Chung
Heounjeong Go
Soyeon Kim
Tae Min Kim
P304
P3181
P356
10.1097/JTO.0B013E318283DCC0
P4510
P50
P577
2013-04-01T00:00:00Z